Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599612 | 0.84 | PARP1 (0.44) | GAA | |
| SCHEMBL15090423 | 0.81 | GAA (0.45) | SMN1; SMN2GAAATAD2 | |
| SCHEMBL27677766 | 0.81 | PDE3B (0.48) | SMN1; SMN2KDM4E | |
| SCHEMBL4353311 | 0.80 | DPYD (0.50) | HTTSMN1; SMN2GAAATAD2 | |
| SCHEMBL13456018 | 0.78 | GAA (0.39) | GAAATAD2 | |
| SCHEMBL7598825 | 0.77 | F13A1 (0.44) | SMN1; SMN2GAA | |
| SCHEMBL156784 | 0.77 | ATAD2 (0.48) | ATAD2 | |
| SCHEMBL7070324 | 0.77 | GAA (0.50) | HTTSMN1; SMN2GAAATAD2 | |
| SCHEMBL30132218 | 0.76 | F13A1 (0.51) | GAA | |
| SCHEMBL31239128 | 0.76 | MAPT (0.38) | HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, ABCB1, SLCO2B1 | HTT 1057/4885SMN1; SMN2 1580/4885GAA 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.